Citadel Advisors
SNOA icon

Citadel Advisors’s Sonoma Pharmaceuticals SNOA Stock Holding History

Citadel Advisors’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,758
Closed -$41.4K – 15169
2024
Q2 		$41.4K Buy
+9,758
New +$34.7K ﹤0.01% 11959
2024
Q1 		– Sell
-5,839
Closed -$21.1K – 15376
2023
Q4 		$21.1K Buy
+5,839
New +$37.2K ﹤0.01% 12580
2022
Q4 		– Sell
-918
Closed -$39K – 15415
2022
Q3 		$39K Sell
918
-366
-29% -$21.4K ﹤0.01% 11774
2022
Q2 		$76K Buy
+1,284
New +$82.2K ﹤0.01% 11639
2019
Q2 		– Sell
-250
Closed -$42K – 9796
2019
Q1 		$42K Buy
+250
New +$37.8K ﹤0.01% 8885
2018
Q4 		– Sell
-60
Closed -$16K – 9705
2018
Q3 		$16K Sell
60
-19
-24% -$6.9K ﹤0.01% 9053
2018
Q2 		$35K Buy
+79
New +$51.5K ﹤0.01% 8520
2016
Q2 		– Sell
-24
Closed -$20K – 7352
2016
Q1 		$20K Sell
24
-7
-23% -$6.5K ﹤0.01% 6460
2015
Q4 		$32K Sell
31
-25
-45% -$26.6K ﹤0.01% 7628
2015
Q3 		$65K Buy
56
+43
+331% +$51K ﹤0.01% 7377
2015
Q2 		$16K Sell
13
-13
-50% -$12.2K ﹤0.01% 8262
2015
Q1 		$20K Buy
+26
New +$22.1K ﹤0.01% 7906

Other funds holding SNOA

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Citadel Advisors's SNOA Position: Q3 2024 in Review

Citadel Advisors sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2024, closing a stake of 9,758 shares — an estimated $41.4K sold.

Citadel Advisors first reported a position in SNOA in Q1 2015 and held it in 12 quarters. The position peaked at $76K in Q2 2022. 14 funds tracked by Wall St. Rank hold SNOA as of Q3 2024.

  • Citadel Advisors reported no remaining Sonoma Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 9,758 Sonoma Pharmaceuticals shares in Q3 2024, an estimated $41.4K.
  • Citadel Advisors first reported a position in Sonoma Pharmaceuticals in Q1 2015 and held it in 12 quarters.
  • Citadel Advisors's Sonoma Pharmaceuticals position peaked at $76K in Q2 2022.
  • 14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.